Nitrazepam, Clonazepam(CZP) antibody/antigen (BSA/OVA/KLH conjugated hapten)
anti-Nitrazepam, Clonazepam(CZP) antibody and Carrier-coupled antigen/immunogen (hapten-carrier conjugates)
Go to Drugs of Abuse diagnostics products collection >>
Product information
Catalog No. | Description | US $ Price (per mg) |
---|---|---|
GMP-SMT-202-1 | 1. BSA-Nitrazepam, Clonazepam(CZP) 2. Anti-Nitrazepam, Clonazepam(CZP) mouse monoclonal antibody | $2709.00 |
GMP-SMT-202-2 | 1. OVA-Nitrazepam, Clonazepam(CZP) 2. Anti-Nitrazepam, Clonazepam(CZP) mouse monoclonal antibody | $2709.00 |
GMP-SMT-202-3 | 1. BSA-Nitrazepam, Clonazepam(CZP) 2. Anti-Nitrazepam, Clonazepam(CZP) human monoclonal antibody | $2709.00 |
GMP-SMT-202-4 | 1. OVA-Nitrazepam, Clonazepam(CZP) 2. Anti-Nitrazepam, Clonazepam(CZP) human monoclonal antibody | $2709.00 |
GMP-SMT-202-Ag-1 | BSA-Nitrazepam, Clonazepam(CZP) | $756.00 |
GMP-SMT-202-Ag-2 | OVA-Nitrazepam, Clonazepam(CZP) | $756.00 |
GMP-SMT-202-Ab-1 | Anti-Nitrazepam, Clonazepam(CZP) mouse monoclonal antibody | $1953.00 |
GMP-SMT-202-Ab-2 | Anti-Nitrazepam, Clonazepam(CZP) human monoclonal antibody | $1953.00 |
Size: 1mg | 10mg | 100mg
Product Description
BSA-Nitrazepam, Clonazepam(CZP)
Cat No. | GMP-SMT-202-Ag-1 |
Bioactivity validation | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody; |
Products description | Competitive immunoassay-validated hapten-carrier conjugates BSA-Nitrazepam, Clonazepam(CZP) with anti-Hapten antibody. The hapten hapten-carrier conjugates BSA-Nitrazepam, Clonazepam(CZP) had been validated with our anti-Hapten antibody Anti-Nitrazepam, Clonazepam(CZP) mouse monoclonal antibody via competitive ELISA test. |
Application | ELISA tests and other immunoassays; Lateral flow immunoassay (LFIA); LTIA Immunonephelometry Time-resolved Fluorescence Immunoassay (TRFIA) |
Formulation | Lyophilized from sterile PBS, PH 7.4 |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
OVA-Nitrazepam, Clonazepam(CZP)
Cat No. | GMP-SMT-202-Ag-2 |
Bioactivity validation | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody; |
Products description | Competitive immunoassay-validated hapten-carrier conjugates OVA-Nitrazepam, Clonazepam(CZP) with anti-Hapten antibody. The hapten hapten-carrier conjugates OVA-Nitrazepam, Clonazepam(CZP) had been validated with our anti-Hapten antibody Anti-Nitrazepam, Clonazepam(CZP) mouse monoclonal antibody via competitive ELISA test. |
Application | ELISA tests and other immunoassays; Lateral flow immunoassay (LFIA); LTIA Immunonephelometry Time-resolved Fluorescence Immunoassay (TRFIA) |
Formulation | Lyophilized from sterile PBS, PH 7.4 |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Anti-Nitrazepam, Clonazepam(CZP) mouse monoclonal antibody
Cat No. | GMP-SMT-202-Ab-1 |
Host of Antibody | Mouse IgG |
Bioactivity validation | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody; Lateral flow immunoassay (LFIA); |
ELISA IC50 (ppb) | 0.9-1 |
Products description | The anti-Hapten antibody against hapten Nitrazepam, Clonazepam(CZP) had been validated with our hapten hapten-carrier conjugates BSA-Nitrazepam, Clonazepam(CZP) via competitive ELISA test. |
Application | ELISA tests and other immunoassays; Lateral flow immunoassay (LFIA); LTIA Immunonephelometry Time-resolved Fluorescence Immunoassay (TRFIA) |
Formulation | Lyophilized from sterile PBS, PH 7.4 |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Anti-Nitrazepam, Clonazepam(CZP) human monoclonal antibody
Cat No. | GMP-SMT-202-Ab-2 |
Host of Antibody | Human IgG1 |
Bioactivity validation | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody; Lateral flow immunoassay (LFIA); |
ELISA IC50 (ppb) | 0.9-1 |
Products description | The anti-Hapten antibody against hapten Nitrazepam, Clonazepam(CZP) had been validated with our hapten hapten-carrier conjugates BSA-Nitrazepam, Clonazepam(CZP) via competitive ELISA test. |
Application | ELISA tests and other immunoassays; Lateral flow immunoassay (LFIA); LTIA Immunonephelometry Time-resolved Fluorescence Immunoassay (TRFIA) |
Formulation | Lyophilized from sterile PBS, PH 7.4 |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Biomarker Information
1. Nitrazepam and Clonazepam (CZP), two distinct small molecules, play crucial roles in the domain of in vitro diagnosis (IVD). Nitrazepam, a pharmaceutical compound commonly prescribed for the treatment of insomnia, and Clonazepam (CZP), primarily employed in managing anxiety disorders and epilepsy, serve as indispensable competitive antigens in immunoassays, contributing significantly to the advancement of diagnostic methodologies. These compounds are pivotal as haptens, which are small molecules capable of being conjugated to carrier proteins such as Bovine Serum Albumin (BSA) or Ovalbumin (OVA). In this context, we delve into the intricate roles and significance of Nitrazepam and Clonazepam (CZP) within IVD.
- Nitrazepam and Clonazepam (CZP) serve as competitive antigens, engendering specific antibody responses in immunoassays designed for the precise quantitative or qualitative detection of their respective metabolites or analogs present within biological specimens. These immunoassays are instrumental in diagnostic testing, clinical research, and pharmaceutical development, rendering Nitrazepam and Clonazepam (CZP) pivotal components of IVD.
- The conjugation of Nitrazepam or Clonazepam (CZP) to carrier proteins affords the generation of antibodies characterized by a high degree of specificity for these compounds. These antibodies serve as the cornerstone in the development of precise and sensitive diagnostic assays, meticulously tailored to detect Nitrazepam or Clonazepam (CZP) and their associated compounds within patient samples.
2. The measurement and quantification of Nitrazepam and Clonazepam (CZP) carry profound significance for a multitude of reasons, each contributing to their vital role in the realms of diagnostics, therapeutic management, research, and patient safety:
- Therapeutic Optimization: Accurate measurement of Nitrazepam and Clonazepam (CZP) levels is of paramount importance in the optimization of therapeutic regimens. Healthcare professionals rely on these measurements to fine-tune medication dosages, thereby achieving optimal therapeutic efficacy while minimizing the risk of adverse effects.
- Compliance and Adherence Assessment: Monitoring the concentrations of these compounds enables healthcare providers to evaluate patient compliance and adherence to prescribed treatment plans. This oversight ensures that patients are receiving the intended therapeutic benefits of Nitrazepam or Clonazepam (CZP) while adhering to recommended dosages and administration schedules.
- Toxicity Identification: Elevated levels of Nitrazepam or Clonazepam (CZP) can lead to toxicity and severe adverse effects. Routine monitoring allows for the early detection of potential overdose situations, prompting timely intervention to mitigate harm and improve patient outcomes.
- Pharmacokinetic Insights: Pharmacokinetic studies rely heavily on the measurement of Nitrazepam and Clonazepam (CZP) concentrations to unravel the intricate dynamics of their absorption, distribution, metabolism, and excretion within the human body. These insights are invaluable in the field of drug development, enabling researchers to optimize formulations and dosing regimens.
- Forensic and Toxicology Applications: In forensic investigations and toxicology assessments, precise quantification of Nitrazepam and Clonazepam (CZP) provides essential information in cases involving drug-related incidents, overdoses, or poisonings. This data aids forensic scientists and toxicologists in unraveling the circumstances surrounding such events.
- Research and Development: Nitrazepam and Clonazepam (CZP) measurements are pivotal in pharmaceutical research and clinical trials. Researchers rely on accurate quantification to assess drug bioavailability, pharmacokinetics, and therapeutic efficacy. This information is instrumental in the development of new pharmaceuticals and the evaluation of their performance in clinical settings.
In summary, the quantification of Nitrazepam and Clonazepam (CZP) plays an indispensable role across diverse domains, ranging from therapeutic optimization and patient safety to diagnostic accuracy and pharmaceutical research. These small molecules serve as essential targets for immunoassays in the field of in vitro diagnosis, contributing to the advancement of medical science and patient care.
About GDU
GDU helps global diagnostic partners in high quality of raw material discovery, development, and application. GDU believes in Protein&antibody Innovation for more reliable diagnostic solutions.